Articles tagged with Leukemia
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
Chromatin accessibility maps reveal that MDS stem cells gradually lose their normal identity and acquire characteristics typical of myeloid progenitors. A 'progenitor score' developed by the team tracks cell movement toward a progenitor-like state, correlating with disease severity and prognosis.
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
A new trial shows pirtobrutinib to be more effective than bendamustine plus rituximab in treating previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug demonstrated improved survival rates, a favorable safety profile, and lower adverse event rates compared to the standard treatment.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
A new treatment using genome-edited immune cells has shown promising results in helping children and adults fight a rare form of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL). The gene therapy, known as BE-CAR7, uses base-editing to modify T-cells and destroy cancerous cells.
A Mount Sinai study found that the timing of a genetic mutation in children with leukemia can significantly impact its aggressiveness. The researchers discovered that leukemia caused by mutations occurring before birth is often more aggressive and harder to treat than those occurring later in life.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met its primary endpoint in terms of overall response rate compared to covalent BTK inhibitor ibrutinib. The study suggests pirtobrutinib shows promise as initial BTK inhibitor therapy for patients with CLL and SLL.
A new study found that a chemo-free combination treatment outperformed targeted therapy and chemotherapy in patients with Ph+ acute lymphoblastic leukemia, achieving higher rates of event-free survival and complete remission. Researchers recommend this approach as the new standard of care for this patient group.
A new trial comparing continuous and fixed-duration treatments for CLL found equivalent outcomes in terms of risk of death or disease progression. Fixed-duration treatment was non-inferior to continuous treatment, suggesting clinically equal efficacy.
Patients with B-acute lymphoblastic leukemia who have no evidence of remaining cancer cells experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation. The study's findings could allow more patients to avoid TBI and its associated long-term side effects.
Black patients with acute myeloid leukemia are diagnosed at younger ages and have worse outcomes compared to white patients, according to a study analyzing data from 10 clinical trials over 34 years. The study found that Black patients had a higher risk of dying from AML and any cause, even when treated with similar mutations.
Researchers found that measurable residual disease (MRD) is strongly associated with long-term outcomes in AML patients, providing a reliable indicator of treatment response. MRD testing may help refine how physicians assess treatment efficacy and personalize post-remission care.
Nearly one-third of families with children being treated for acute lymphoblastic leukemia (ALL) experience serious financial difficulties, including losing 25% or more of their household income. The study, led by Dr. Daniel Zheng, found that nearly a third of families struggled to meet basic living costs during their child's treatment.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
Researchers have developed a system called CytoDiffusion that uses generative AI to study the shape and structure of blood cells. The system can accurately identify normal blood cell appearances and spot unusual or rare cells that may indicate disease, outperforming existing systems in tests.
The study reveals that mutated and unmutated CLL subtypes originate from distinct stages of B cell development. New molecular biomarkers, including genes LPL, ZNF667, and ZNF667-AS1, have been identified for more precise patient stratification.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Researchers identified a new subtype of T-cells that do not respond to current treatments and could impact clinical care. A genetic marker, ZBTB16, was found to be switched on in these cells, which can be used to identify them.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
A combination treatment of ibrutinib and ianalumab allowed some patients with CLL to discontinue daily therapy and potentially improve their quality of life. The study found that 43.6% of patients had undetectable measurable residual disease, and 17 patients were able to stop ibrutinib and remain off therapy for 12 to 24 months.
Scientists at St. Jude Children's Research Hospital identified a mechanism behind pro-cancer gene expression in a high-risk AML subtype. Inhibiting Exportin-1 showed promise as a novel strategy to treat UBTF-TD AML, which is characterized by treatment resistance and relapse.
Researchers have identified a new histone variant, macroH2A1.1, as a potential therapeutic target for treating Acute Myeloid Leukaemia. The study found that targeting this variant is safe for patients and may lead to new treatment options.
Scientists re-engineered a common chemotherapy drug to make it more soluble and effective, targeting cancer cells while leaving healthy tissues unharmed. The new nanomedicine significantly extended survival in animal models of leukemia, showing promise for improved cancer treatment.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Researchers found a protein that lets cancer cells reshape their mitochondria to protect themselves from venetoclax, a standard treatment for acute myeloid leukemia. Blocking this protein with experimental compounds restored the drug's effectiveness and prolonged survival in mice.
The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Researchers at the University of Cambridge have developed a new lab-grown human embryo model that replicates early human development, including the production of blood stem cells. The 'hematoids' model mimics the natural developmental process, offering potential medical advances in screening drugs and studying blood disorders.
Scientists at Institut Pasteur and Inserm developed a triple-therapy approach to treat blood cancers like lymphomas and leukemias. They induced necroptosis in malignant B cells, which activates the immune system to eliminate tumor cells.
A study of 9/11 first responders found mutations in blood-forming cells may explain increased leukemia risk, suggesting a targeted intervention against environmental toxins. The research also identified IL1RAP as a protein culprit, which could be used to prevent or treat blood cancers in individuals exposed to similar disasters.
A Virginia Tech oncologist is championing a precise approach to treating acute myeloid leukemia by tracking subtle molecular changes in patients. His work aims to identify signs of potential relapse and tailor treatment for each individual with this rare blood cancer.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
Researchers identified two lymphocyte subpopulations associated with arsenic trioxide therapy for APL, the CD8 ISG T cells and NK NFκB cells, which provide new insights into its mechanism of action. ATO treatment also revitalized dysfunctional NK cells and remodelled immunoglobulin proteins.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A team of researchers led by Dr. Manel Esteller has published a study on the longest-lived person ever recorded, Maria Branyas, who reached 117 years. The analysis reveals a fascinating duality: simultaneous presence of signals of extreme aging and healthy longevity. Despite signs of aging, Branyas had genetic characteristics associate...
Researchers developed a groundbreaking diagnostic tool called MARLIN to classify acute leukemia with speed and accuracy using DNA methylation patterns and machine learning. The tool demonstrates high accuracy for disease classification in under two hours from the time of biopsy, providing rapid insights into leukemia subtypes.
A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.
A federally funded study found children with leukemia who were exposed to pesticides during their mother's pregnancy had a higher risk of death. The study, published in Cancers, examined over 800 children and showed pesticide exposure increased child mortality by up to 60%.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers have identified a previously unknown molecular mechanism behind chemoresistance in acute myeloid leukemia (AML), a type of blood cancer. The study found that a protein called RUNX1C plays a key role in this process, and blocking its activity with RNA-targeting tools can improve chemotherapy's effectiveness.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Researchers have identified a key synergistic role for two epigenetic markers involved in programming cell fate. Turning off these markers causes genes to over-activate, disrupting normal cell development. This discovery may indicate a new target for treating some types of leukemia with drugs already in clinical trials for other cancers.
Researchers discovered cancer cells can survive within bone marrow fibroblasts in response to BTK inhibitors, leading to higher survival rates. By blocking CXCR4, treatment may become more effective, potentially increasing complete response rates and moving toward a cure for cancer
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
Researchers from Kumamoto University identified a genetic 'silencer' element that keeps the human T-cell leukemia virus type 1 (HTLV-1) in a dormant state, evading immune detection. This discovery offers hope for new therapeutic approaches to treat HTLV-1 and potentially even HIV.
A study found that immunoglobulin replacement therapy was ineffective in reducing serious infections requiring hospitalization among CLL patients. Despite increasing use of the therapy, infection rates remained high, highlighting a need for better clinical guidelines and evaluation of treatment duration.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
A new study found that exercise can improve the quality of life and symptom management for CLL patients, but personalized guidance is needed. Patients prefer virtual classes, expert advice from cancer care specialists, and tailored programs addressing their unique challenges.